Supreme Court questions systemic bias favouring pharmaceutical manufacturers

The Supreme Court of India on Tuesday questioned whether the entire system has been structured to favour pharmaceutical manufacturers, raising concerns about potential institutional bias in the sector's regulation and oversight.

During hearings, the bench expressed skepticism about the balance between protecting public health interests and pharmaceutical industry interests, suggesting that various regulatory bodies and mechanisms may be tilted disproportionately toward manufacturers' convenience and profit margins.

The court's observations point to broader questions about how India's pharmaceutical regulatory framework functions, including the approval processes, pricing mechanisms, and enforcement practices that govern one of the world's largest pharmaceutical industries.

The Supreme Court's intervention underscores growing judicial scrutiny of pharmaceutical sector practices in India, particularly regarding drug accessibility, pricing, and regulatory compliance. The bench indicated it would examine whether existing safeguards adequately protect consumer and public health interests against manufacturer-friendly policies.

No specific ruling was issued during the hearing, but the court's remarks signal potential future interventions in pharmaceutical regulation to ensure a more equitable balance between industry and public welfare considerations.